Immunomedics, Inc. (IMMU) Stake Increased by California Public Employees Retirement System

California Public Employees Retirement System lifted its stake in shares of Immunomedics, Inc. (NASDAQ:IMMU) by 33.0% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 154,647 shares of the biopharmaceutical company’s stock after acquiring an additional 38,347 shares during the quarter. California Public Employees Retirement System’s holdings in Immunomedics were worth $2,162,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the company. Amalgamated Bank lifted its position in shares of Immunomedics by 8.1% during the 2nd quarter. Amalgamated Bank now owns 12,911 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 966 shares during the last quarter. Raymond James Financial Services Advisors Inc. lifted its position in shares of Immunomedics by 11.4% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 14,400 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 1,473 shares during the last quarter. Legal & General Group Plc lifted its position in shares of Immunomedics by 7.4% during the 2nd quarter. Legal & General Group Plc now owns 25,477 shares of the biopharmaceutical company’s stock worth $222,000 after buying an additional 1,747 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Immunomedics by 2.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 79,520 shares of the biopharmaceutical company’s stock worth $702,000 after buying an additional 1,763 shares during the last quarter. Finally, Voya Investment Management LLC lifted its position in shares of Immunomedics by 5.9% during the 2nd quarter. Voya Investment Management LLC now owns 50,433 shares of the biopharmaceutical company’s stock worth $445,000 after buying an additional 2,808 shares during the last quarter. Institutional investors and hedge funds own 76.28% of the company’s stock.

Shares of Immunomedics, Inc. (NASDAQ IMMU) opened at $15.84 on Friday. Immunomedics, Inc. has a 12-month low of $4.08 and a 12-month high of $17.24. The company has a market cap of $2,410.00, a price-to-earnings ratio of -7.07 and a beta of 1.48. The company has a debt-to-equity ratio of -0.29, a current ratio of 0.74 and a quick ratio of 0.74.

Immunomedics (NASDAQ:IMMU) last released its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.06). equities analysts forecast that Immunomedics, Inc. will post -1.16 earnings per share for the current year.

Several brokerages have recently weighed in on IMMU. Zacks Investment Research downgraded shares of Immunomedics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 15th. Jefferies Group boosted their price objective on shares of Immunomedics from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Monday, October 9th. BidaskClub upgraded shares of Immunomedics from a “hold” rating to a “buy” rating in a research report on Friday, December 22nd. Finally, ValuEngine downgraded shares of Immunomedics from a “hold” rating to a “sell” rating in a research report on Friday, January 5th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. Immunomedics has an average rating of “Buy” and a consensus target price of $15.33.

In other Immunomedics news, Director Venbio Select Advisor Llc purchased 1,150,000 shares of Immunomedics stock in a transaction that occurred on Tuesday, November 14th. The stock was purchased at an average price of $10.39 per share, for a total transaction of $11,948,500.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Behzad Aghazadeh purchased 1,325,000 shares of Immunomedics stock in a transaction that occurred on Wednesday, November 15th. The stock was acquired at an average price of $10.47 per share, with a total value of $13,872,750.00. The disclosure for this purchase can be found here. 6.60% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This story was posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.themarketsdaily.com/2018/01/19/immunomedics-inc-immu-stake-increased-by-california-public-employees-retirement-system.html.

Immunomedics Profile

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Want to see what other hedge funds are holding IMMU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunomedics, Inc. (NASDAQ:IMMU).

Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply